topotecan has been researched along with amrubicin in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (33.33) | 29.6817 |
2010's | 8 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Harita, S; Hotta, K; Kiura, K; Kuyama, S; Nogami, N; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Tada, A; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
Ettinger, DS | 1 |
Gomi, K; Hommura, F; Inage, M; Inoue, A; Inoue, C; Ishimoto, O; Maemondo, M; Nukiwa, T; Saijo, Y; Sugawara, S; Suzuki, T; Takanashi, S; Tsukamoto, T; Watanabe, H; Yamazaki, K; Yokouchi, H | 1 |
Hann, CL; Rudin, CM | 1 |
Conkling, P; Fitzgibbons, JF; Galsky, MD; Jotte, R; Klein, L; McNally, R; Oliver, JW; Renschler, MF; Reynolds, C | 1 |
Chikamori, K; Harita, S; Hosokawa, S; Hotta, K; Kishino, D; Kiura, K; Kuyama, S; Nogami, N; Shibayama, T; Shinkai, T; Tabata, M; Takigawa, N; Tamaoki, A; Tanimoto, M; Ueoka, H | 1 |
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
Bosquée, L; Bubis, J; Clingan, P; Domine, M; Jotte, R; Li, S; Lorigan, P; Mezger, J; Nackaerts, K; O'Brien, ME; Reck, M; Renschler, MF; Schütte, W; Shepherd, FA; Socinski, MA; Spigel, DR; Steins, M; Trigo, JM; von Pawel, J | 1 |
Horita, N; Ikeda, M; Kaneko, T; Kobayashi, N; Kudo, M; Nagai, K; Nagakura, H; Nakashima, K; Sato, T; Shibata, Y; Shinkai, M; Tashiro, K; Tsukahara, T; Ushio, R; Watanabe, H; Yamamoto, M | 1 |
Casaluce, F; Gridelli, C; Maione, P; Palazzolo, G; Rossi, A; Sacco, PC; Santabarbara, G; Sgambato, A | 1 |
Benedetti, F; Cortinovis, D; Galetta, D; Inoue, A; Kubota, K; Makris, L; Niho, S; Nishio, M; Satouchi, M; Scagliotti, G; Valmadre, G; Yoshihara, E | 1 |
Nazha, B; Owonikoko, TK | 1 |
4 review(s) available for topotecan and amrubicin
Article | Year |
---|---|
Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific?
Topics: Anthracyclines; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Europe; Humans; Japan; Lung Neoplasms; Topotecan; United States | 2007 |
Management of small-cell lung cancer: incremental changes but hope for the future.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2008 |
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients.
Topics: Anthracyclines; Antineoplastic Agents; Asian People; Humans; Japan; Lung Neoplasms; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome; White People | 2016 |
Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antineoplastic Agents; Humans; Immunotherapy; Ipilimumab; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan | 2016 |
6 trial(s) available for topotecan and amrubicin
Article | Year |
---|---|
A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carcinoma, Small Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome | 2006 |
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Topics: Aged; Anthracyclines; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan | 2008 |
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan; United States | 2011 |
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Disease-Free Survival; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Odds Ratio; Polymorphism, Single Nucleotide; Proportional Hazards Models; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome; Young Adult | 2014 |
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Platinum; Pyrrolidines; Small Cell Lung Carcinoma; Thymine; Topotecan; Treatment Outcome; Trifluridine; Uracil | 2016 |
2 other study(ies) available for topotecan and amrubicin
Article | Year |
---|---|
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |